Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United Sates.
Vitam Horm. 2023;123:249-284. doi: 10.1016/bs.vh.2023.03.001. Epub 2023 Mar 30.
The peptide hormone hepcidin is central to the regulation of iron metabolism, influencing the movement of iron into the circulation and determining total body iron stores. Its effect on a cellular level involves binding ferroportin, the main iron export protein, preventing iron egress and leading to iron sequestration within ferroportin-expressing cells. Hepcidin expression is enhanced by iron loading and inflammation and suppressed by erythropoietic stimulation. Aberrantly increased hepcidin leads to systemic iron deficiency and/or iron restricted erythropoiesis as occurs in anemia of chronic inflammation. Furthermore, insufficiently elevated hepcidin occurs in multiple diseases associated with iron overload such as hereditary hemochromatosis and iron loading anemias. Abnormal iron metabolism as a consequence of hepcidin dysregulation is an underlying factor resulting in pathophysiology of multiple diseases and several agents aimed at manipulating this pathway have been designed, with some already in clinical trials. In this chapter, we assess the complex regulation of hepcidin, delineate the many binding partners involved in its regulation, and present an update on the development of hepcidin agonists and antagonists in various clinical scenarios.
肽激素铁调素是铁代谢调节的核心,影响铁向循环中的转移,并决定全身铁储存量。其在细胞水平上的作用涉及与铁输出蛋白 ferroportin 结合,阻止铁外流,导致 ferroportin 表达细胞内铁的蓄积。铁负荷和炎症会增强铁调素的表达,而促红细胞生成刺激会抑制其表达。异常增加的铁调素会导致全身缺铁和/或铁受限性红细胞生成,如慢性炎症性贫血中所发生的情况。此外,在多种与铁过载相关的疾病中,如遗传性血色素沉着症和铁负荷性贫血,铁调素的表达水平不足。铁调素失调导致的异常铁代谢是多种疾病的病理生理学基础,已有多种旨在操纵该途径的药物被设计出来,其中一些已经在临床试验中。在本章中,我们评估了铁调素的复杂调节,描述了其调节中涉及的许多结合伴侣,并介绍了在各种临床情况下铁调素激动剂和拮抗剂的开发进展。